#psilocybintherapy — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #psilocybintherapy, aggregated by home.social.
-
DATE: September 10, 2026 at 08:00AM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Psilocybin prevents chemotherapy-induced nerve damage in new preclinical study
Recent research suggests that giving mice a compound found in magic mushrooms before chemotherapy can prevent the debilitating nerve damage that often accompanies cancer treatment. The findings indicate that psilocybin protects nerve fibers by keeping their cellular powerhouses moving and functioning properly. The study was published in Science.
Chemotherapy-induced peripheral neuropathy is a condition where cancer drugs damage the long sensory nerves that extend from the spinal cord to the hands and feet. This damage leads to pain, numbness, and an extreme sensitivity to cold. Because the condition can be severe and long-lasting, doctors often have to reduce a patient’s chemotherapy dose or stop the treatment entirely.
“Almost everyone who gets any of the most common cancer chemotherapies for all the most common cancers will develop peripheral neuropathy that can be experienced as mild numbness, tingling, to pins and needles or to most severe as continuous burning sensations,” said study co-author Patrick M. Dougherty, a professor of pain medicine research at The University of Texas MD Anderson Cancer Center.
“This is in spite of the fact that none of these cancer drugs are given at the maximum dose to kill cancer cells, but at lesser doses to avoid neurotoxicity,” he told PsyPost. “While many patients will improve over time, others suffer this negative impact for years.”
Medical scientists have worked to understand exactly how these drugs harm the nerves. For example, a 2014 review established that chemotherapy agents tend to damage mitochondria, the small structures inside cells that generate energy. These energy factories are especially important for sensory nerves, which require a constant supply of power along their extensive, thread-like extensions, called axons.
Subsequent work, such as a 2024 study, demonstrated that keeping mitochondria moving along these nerve fibers helps shield them from the physical degeneration caused by chemotherapy. In a parallel area of study, a 2018 study provided evidence that psychedelic compounds can stimulate specific growth pathways to rebuild and protect nerve connections.
The authors of the new study connected these pieces of evidence. Psilocybin, the active ingredient in certain mushroom species, activates a specific receptor on the surface of cells known as the serotonin 2A receptor. Because this receptor is involved in both nerve adaptability and mitochondrial regulation, the scientists hypothesized that administering psilocybin before chemotherapy might trigger a protective rescue mechanism, preventing the nerve damage before it begins.
“Interventions for pre-established neuropathy have not worked out, so the goal here was to find a way to protect the nervous system to keep neuropathy from ever developing,” Dougherty explained.
“There is an urgent need for treatments that prevent nerve injury without interfering with lifesaving chemotherapy,” added study co-leader Moran Amit, an assistant professor of head and neck surgery at The University of Texas MD Anderson Cancer Center. “These findings offer important insights into how psilocybin may protect nerves before damage occurs, rather than treating symptoms after they become persistent.”
The research, co-led by Dougherty and Amit, utilized a combination of mouse behavioral models and human tissue analysis. To test their hypothesis, the scientists gave mice two doses of psilocybin before administering common chemotherapy drugs, such as cisplatin and paclitaxel. They then subjected the mice to up to six cycles of chemotherapy, mimicking a clinical treatment schedule.
To measure nerve damage, the researchers tested the animals’ responses to physical pressure and cold temperatures over the course of eight months. The team also used mice with oral tumors to check if psilocybin interfered with the chemotherapy’s ability to shrink the cancer.
In addition to the animal models, the researchers examined human sensory neurons grown in the lab. They also looked at fresh peripheral nerve tissue taken from 29 human surgical patients. Using advanced live-cell imaging, they watched how mitochondria moved inside these human nerve fibers when exposed to chemotherapy with and without psilocybin.
The scientists found that just two preventive doses of psilocybin kept the mice from developing the physical hypersensitivity and cold sensitivity typically caused by the chemotherapy drugs. The mice maintained normal baseline sensitivity scores, and this protective effect lasted across all six cycles of treatment and throughout the eight-month follow-up period.
Notably, psilocybin did not reduce the cancer-killing effectiveness of the chemotherapy. The tumor-bearing mice that received psilocybin showed the same reduction in tumor size as those that only received chemotherapy. Systemic immune markers also remained unchanged, suggesting the treatment targets the nerves without altering the body’s general response to cancer.
The team discovered that psilocybin operates through two distinct pathways to achieve this protection. In the brain, it helped normalize electrical activity that is typically disrupted by chronic pain. In the peripheral body, it directly protected the structure and function of the sensory nerve endings in the skin.
When looking closely at the nerve cells, the researchers noticed that chemotherapy ordinarily causes mitochondria to stall, halting their journey down the long nerve axons. This starvation of energy at the distant nerve endings leads to their structural decay. Psilocybin prevented this traffic jam.
By activating the serotonin 2A receptor, psilocybin engaged a specific signaling chain that controls the molecular motors responsible for transporting mitochondria. By keeping the mitochondria moving, psilocybin ensured the nerve endings received the energy they needed to survive the toxic stress of the chemotherapy.
“Psilocybin does more than reduce pain signals by protecting the nerves themselves through energy delivery,” Dougherty noted. “This neuroprotective effect could help patients withstand the stress of chemotherapy, maintaining sensation, mobility and quality of life during treatment and long into survivorship.”
The researchers also found that the hallucinogenic effects of psilocybin were not strictly necessary for this nerve protection. When they treated mice with a nonhallucinogenic compound that targets the exact same serotonin 2A receptors, the animals received an equivalent level of protection against the nerve damage.
The findings are in line with research covered by PsyPost in 2026, which found that a single dose of psilocybin reduced neuropathic pain sensitivity in mice. It is worth noting that the older study evaluated treating established pain via central brain remodeling, whereas the new study evaluated preventing the pain prophylactically by preserving peripheral nerve function. Another study covered by PsyPost later in 2026 similarly demonstrated psilocybin’s ability to calm pain networks in rodents, again focusing on existing central pain rather than preventing peripheral damage.
As with all research, there are some caveats to consider. The study relies heavily on mouse models and isolated human tissues. Laboratory tests on human nerve cells provided promising outcomes, but clinical trials involving human patients are needed to see if the preventive treatment works safely and effectively in a real-world medical setting.
“The study offers an interesting mechanistic and preclinical rationale for investigating psilocybin in chemotherapy-induced peripheral neuropathy, particularly through its potential effects on mitochondrial trafficking and neuronal resilience,” said Andres Ort, a physician and member of the Neurophenomenology of Consciousness Lab at the University of Zurich who was not involved in the research.
“However, the findings should not be interpreted as evidence that psilocybin prevents or treats chemotherapy-induced neuropathy in patients,” Ort told PsyPost. “The translational gap between experimental models and clinical oncology remains substantial, and questions around dosing, timing, safety, drug interactions, psychiatric screening, blinding, and meaningful patient-centered outcomes will need careful evaluation.”
“The prospect of self-medication would be best avoided,” Dougherty cautioned. “If the work is validated, access to psilocybin would come to be available through your oncologist.”
It is also important to note that the timing of the treatment appears strict. The study indicates that psilocybin only works as a preventive measure in this context. When the researchers tried administering chemotherapy first and waiting for the nerve damage to set in, the psilocybin did not reverse the injury. Patients would likely need to receive the compound before every cycle of chemotherapy to maintain the protective effect.
Despite these constraints, the researchers are optimistic about the drug’s clinical potential. “The results of this study are very promising and have opened a new angle for potential therapeutic intervention in chemotherapy-induced peripheral neuropathy,” Dougherty said.
The team is already moving forward with an upcoming Phase 2 clinical trial, called NeuroGuard, to evaluate psilocybin during chemotherapy in patients with multiple cancer types. “A clinical trial will be opening soon for patients receiving cisplatin, but other chemotherapies will now also need to be tested to determine whether psilocybin may protect from their neurotoxicities,” Dougherty added.
“The most important next step is a well-designed, adequately powered clinical trial assessing not only neuropathy symptoms, but also function, quality of life, cancer-treatment adherence, and safety in the relevant oncology population,” Ort noted.
“If this work holds up, it may be a therapy integrated to all cancers,” Dougherty explained. “This would impact the approximately 2,000,000 new cancer cases expected in 2026, based on 2025 numbers in just the US.”
This work is part of UT MD Anderson’s Cancer Neuroscience Program, which examines the interactions between cancer and the nervous system. “At UT MD Anderson, we are actively exploring the multiple facets of psychedelics to pursue interventions that improve the lives of our patients,” Amit concluded.
The study, “Psilocybin prevents chemotherapy-induced peripheral neuropathy through mitochondrial trafficking preservation,” was authored by Mario Heles, Lilach Pasvolsky, Hinduja Sathishkumar, Shorook Naara, Yen Vu, Caitlyn L. Stewart, Tongxin Xie, Frederico O. Gleber-Netto, William McCarthy, Dan Yaniv, Shashank S. Kamal, Hajira Elahi, Pengyu Zhu, Megan L. Uhelski, Jordan Chatwin, Andrew Lara, Danielle L. Stolley, Michael R. Migden, Z-Hye Lee, Shiyanth Thevasagayampillai, Preethi H. Gunaratne, Kaoutar Ait-Ahmad, M. J. Kuykendall, Sebnem Ece Eksi, Lorenzo Cohen, Jeremy C. Borniger, Eyal Gottlieb, Gregory H. Jones, Patrick M. Dougherty, and Moran Amit.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #PsilocybinTherapy #ChemotherapyNeuropathy #MitochondrialTrafficking #NerveProtection #PeripheralNeuropathyPrevention #Serotonin2A #PsychedelicsInMedicine #CancerTreatmentSupport #NeuroGuardTrial #ScienceNews
-
DATE: September 2, 2026 at 06:00PM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Psilocybin therapy shows strong potential for treating cocaine addiction
URL: https://www.psypost.org/psilocybin-therapy-shows-strong-potential-for-treating-cocaine-addiction/
Two newly published studies suggest that psychedelic compounds may offer a novel approach to treating cocaine addiction. A clinical trial published in JAMA Network Open found that psilocybin combined with psychotherapy helped people stop using cocaine. A complementary animal study published in Addiction Biology indicates that while psychedelics can help unlearn drug-seeking behaviors, pairing them with the right environmental support might be needed to prevent long-term relapse.
Cocaine use disorder is a chronic condition in which a person compulsively seeks and uses cocaine despite negative consequences to their health, finances, and personal life. Medical treatments for the disorder have long been lacking. For example, a 2021 review evaluated available treatments for cocaine addiction, highlighting that few medical options successfully help people stop using the drug.
To address this gap, researchers have begun exploring classic psychedelics. Psilocybin is the main psychoactive compound found in certain types of mushrooms, known for altering perception, mood, and cognitive processes. Recent studies have tested its potential to treat various substance use disorders by combining the drug with professional psychological support.
The results from these trials have been encouraging. For instance, a 2022 clinical trial found that psilocybin combined with therapy substantially reduced heavy drinking in people with alcohol addiction. Similarly, a 2026 trial found that the treatment helped people quit smoking cigarettes at much higher rates than standard nicotine patches.
Building on this research progression, scientists wanted to test whether psilocybin could yield similar benefits for cocaine use disorder. At the same time, preclinical researchers, who conduct studies using animal or lab models before testing in humans, sought to understand exactly how psychedelics influence the biological and behavioral mechanisms of addiction in isolation, without the influence of human psychotherapy.
The human clinical trial was led by Peter S. Hendricks at the University of Alabama at Birmingham. The team recruited 40 adults diagnosed with cocaine use disorder who wanted to quit using the drug. The participants were randomly assigned to receive either a single oral dose of psilocybin or an active placebo. An active placebo is a control substance that produces mild noticeable side effects so participants cannot easily guess they received a fake treatment. In this case, the placebo was a dose of diphenhydramine, a common antihistamine.
Both groups participated in a structured psychotherapy program that included cognitive-behavioral techniques, which are therapy methods that help people identify and change harmful thought patterns and behaviors. They attended preparation sessions before the drug administration day and integration sessions afterward to process their experiences. The researchers specifically recruited individuals from demographic groups that are often underrepresented in psychedelic research. In the final sample, 82.5 percent of participants were Black, and 65 percent reported an annual income of $20,000 or less.
The findings suggest that psilocybin paired with therapy provides a strong protective effect against cocaine use. Over the 180 days following the treatment session, participants in the psilocybin group reported substantially more days without using cocaine compared to the placebo group. During the final three months of the study, the psilocybin group had about 28 more abstinent days out of every 100 days than the control group.
Additionally, the treatment helped a portion of participants stop using the drug entirely. Over the 180-day follow-up, 30 percent of those who received psilocybin maintained complete abstinence from cocaine. By comparison, none of the participants in the placebo group achieved complete abstinence over that same period.
To understand the isolated pharmacological effects of these treatments, meaning how the drugs interact chemically with the body and brain, a related animal study was led by Isis Rita Anzel Koutrouli at the National Institute of Mental Health in the Czech Republic. The team investigated how psilocybin and a different psychedelic compound, ibogaine, alter the learning processes associated with addiction. Ibogaine is a psychoactive substance derived from an African shrub that has been historically noted for its potential anti-addictive properties, though it operates differently in the brain than psilocybin.
The researchers trained male Wistar rats, a specific and widely used laboratory strain of white albino rats, to self-administer cocaine by pressing a lever. After the rats developed a reliable cocaine habit, the researchers initiated an extinction phase. During this phase, pressing the lever no longer provided the drug. The goal of extinction training is for the subject to unlearn the association between the action and the reward.
On the first and fifth days of the extinction phase, the rats were given injections of either psilocybin, ibogaine, or a saline placebo. Both psychedelics accelerated the extinction process. Rats treated with ibogaine pressed the lever less frequently starting after the first dose. Those treated with psilocybin showed a similar reduction in drug-seeking behavior following the second dose. Both drugs seemed to stabilize the animals’ behavior, helping them abandon the futile lever-pressing habit more efficiently than the placebo group.
The effects, however, did not translate to total relapse prevention. Six days after the final psychedelic dose, the researchers tested the rats by reintroducing the lights and sounds that had previously been paired with cocaine delivery. This triggers cue-induced reinstatement, a model of relapse. When faced with these triggers, the rats treated with psychedelics resumed pressing the lever just as frequently as the rats given the placebo.
These animal results highlight a nuanced reality about psychedelic treatments. The pharmacological effects of compounds like psilocybin and ibogaine appear to enhance behavioral flexibility, making it easier to break old habits. Yet, without the continuous environmental support or active psychotherapy provided in the human trial, the drugs alone did not block the urge to relapse when familiar drug cues returned.
The success seen in the human trial is in line with research covered by PsyPost in 2025, which found that a single dose of psilocybin paired with psychotherapy substantially reduced heavy drinking days in individuals with alcohol use disorder. The results also align with a 2026 study covered by PsyPost, which found that psilocybin and counseling produced higher rates of verified abstinence in cigarette smokers compared to standard nicotine patches.
As with all research, there are a few things to keep in mind. The human clinical trial featured a relatively small number of participants, which means the exact size of the treatment effect could vary in larger populations. Additionally, it is difficult to keep participants unaware of which treatment they receive in psychedelic studies, as the perceptual effects of the drug are very obvious. In this trial, 90 percent of the participants in the psilocybin group correctly guessed their assignment, which introduces the possibility that their expectations influenced their outcomes.
For the animal study, the researchers only tested male rats to avoid behavioral variations related to reproductive cycles. Testing female animals in the future will be necessary to see if the extinction-enhancing effects apply universally. The animal model also strips away the psychological and social elements of human addiction treatment. The rats did not receive the equivalent of human psychotherapy, which might be exactly why the drugs failed to protect them from cue-induced relapse.
Future research will need to test these interventions in larger, more diverse human samples to confirm the benefits. Scientists also hope to refine animal models to better understand how therapeutic environments interact with the biological changes caused by psychedelics.
The study, “Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial,” was authored by Peter S. Hendricks, Sara N. Lappan, Richard C. Shelton, Adrienne C. Lahti, Karen L. Cropsey, Matthew W. Johnson, Melissa Bradley, Otto Simonsson, Lori L. Davis, Daniel H. Grossman, and Cynthia E. Ortiz.
The study, “Psilocybin and Ibogaine in Cocaine-Seeking: Extinction Enhancement Without Relapse Prevention,” was authored by Isis Rita Anzel Koutrouli, Vojtěch Brejtr, Marek Schwendt, Kacper Witek, Chrysostomos Charalambous, Kristýna Aleksič, Nina Miniariková, Eva Lhotková, Martin Toman, Marek Nikolič, Radek Jurok, Petra Cihlářová, Vladimír Mazoch, Pavel Ryšánek, Martin Kuchař, Klára Šíchová, and Tomáš Páleníček.
URL: https://www.psypost.org/psilocybin-therapy-shows-strong-potential-for-treating-cocaine-addiction/
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #PsilocybinTherapy #CocaineUseDisorder #PsychedelicResearch # AddictionTreatment #PsychotherapySupport #AbruptRelapsePrevention #AlcoholNicotineCocaine #ExtinctionTraining #PsyPost #ClinicalTrialResults
-
DATE: August 29, 2026 at 09:00AM
SOURCE: PSYPOST.ORG** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------TITLE: Psilocybin reverses depressive behaviors and restores brain cell growth in stressed rats
Two doses of the psychedelic compound psilocybin can reverse signs of depression and anxiety in rats exposed to chronic stress. The substance appears to work by encouraging the growth of new brain cells and normalizing stress hormone levels. The research was published in Progress in Neuropsychopharmacology & Biological Psychiatry.
Major depressive disorder affects millions of people worldwide. Its core symptoms include persistent low mood, severe anxiety, and an inability to feel pleasure. The condition is associated with a loss of synaptic connections in areas of the brain responsible for regulating emotions. Current medications, such as selective serotonin reuptake inhibitors, do not work for every patient and often take weeks to show any benefit.
Researchers are increasingly looking toward psychedelic substances as alternative therapies. Psilocybin is the active compound found in “magic mushrooms” and has shown promise in treating depression in human trials. Scientists are trying to figure out exactly how the chemical alters the brain to produce these lasting benefits.
Prolonged psychological stress can physically alter the brain by reducing the formation of new connections between neurons. Chronic stress also hyperactivates the body’s natural response to threats, leading to an overproduction of stress hormones from the adrenal glands. Over time, this hormonal flood impairs a region of the brain called the hippocampus, which handles emotion and memory.
Agnieszka Bysiek and Krystyna Gołembiowska, researchers at the Polish Academy of Sciences, led an investigation into how psilocybin might repair this stress-induced damage. They worked alongside colleagues from the Medical University of Warsaw. The team designed an experiment to track behavioral changes and biological markers of brain healing.
The researchers conducted a small study using adult male rats. They divided the animals into groups and exposed one group to a routine of unpredictable mild stressors over several weeks. These stressors included temporary food or water deprivation, tilted cages, and strobe lights.
The goal was to induce a state similar to human depression, particularly a loss of pleasure known as anhedonia. To measure this loss of pleasure, the researchers tracked how much sweetened water the rats chose to drink. The stressed animals drank substantially less sugar water than the unstressed control group.
The researchers then administered two low doses of psilocybin to the animals, spaced one week apart. Following the treatment, the stressed rats resumed drinking the sweetened water at normal levels. This behavioral shift indicated that the psychedelic compound had effectively reversed their anhedonia.
Next, the team evaluated anxiety-like behavior using specialized laboratory enclosures. One test used a box divided into a brightly lit area and a dark compartment, while another used an elevated maze with both open and enclosed walkways. Stressed rats naturally avoided the light and open spaces, seeking the safety of the dark or enclosed areas.
Following the psilocybin treatment, these stressed animals spent more time exploring the bright and open sections of the enclosures. This change in movement patterns suggested a marked reduction in anxiety. The researchers also monitored the animals for head shakes, a common physical reaction in rodents that indicates a drug is causing hallucinatory effects. Both the stressed and non-stressed rats exhibited these shakes after receiving psilocybin.
The researchers also observed the rats in a cylinder filled with water to measure behavioral despair. Rats that simply float without trying to escape are considered to be exhibiting a depressive-like lack of motivation. The psilocybin treatment reduced this immobility, causing the stressed rats to actively swim and climb the walls of the cylinder.
To ensure the animals were not simply experiencing general hyperactivity from the drug, the team placed them in a large, circular open arena. The stressed rats given psilocybin walked around and explored the center of the arena more than untreated stressed rats. The psilocybin actually reduced walking and exploration in the non-stressed control rats.
The team then examined the brains of the animals to understand the biological changes driving these behavioral shifts. They used chemical markers to identify newly formed cells in the hippocampus. The chronic stress had suppressed the creation of new neurons in this region.
The psilocybin injections reversed this cellular deficit. The drug promoted the proliferation, maturation, and survival of new brain cells in the stressed rats. This finding supports the idea that psychedelics help the brain rewire itself by physically growing new cellular architecture.
The researchers also analyzed the genetic expression of a molecule called brain-derived neurotrophic factor. This protein helps neurons grow and form new synaptic connections. They found that psilocybin boosted the genetic instructions for producing this growth protein in both the hippocampus and the prefrontal cortex.
This boost in genetic signaling was apparent just two hours after the first dose. The elevated signals persisted for two weeks after the second dose in the stressed animals. Finally, the researchers measured corticosterone, a major stress hormone in rodents.
The chronically stressed rats had elevated levels of this hormone in their blood. A single dose of psilocybin brought these hormone levels back down to normal within two hours. Fourteen days after the second dose, the stressed animals still maintained lower, healthier hormone levels.
The study comes with a few limitations that provide context for the results. Animal models of depression do not perfectly map onto complex human psychological conditions. The testing environment also heavily influenced the behavior of the rodents, as the animals reacted differently depending on whether they were in an open arena or an enclosed box.
The biological measurements also require a measured interpretation. The research team measured the messenger RNA for the brain growth protein rather than the actual protein itself. Messenger RNA acts as a temporary set of genetic instructions translated from DNA. An increase in these instructions does not always guarantee a proportional increase in the final functional protein product within the brain’s cells.
Future research will need to measure the actual protein levels in the brain to confirm that the biological building blocks were fully assembled. Scientists also plan to investigate how long these cellular changes last after the psychedelic compound leaves the body.
The research provides a foundation for understanding how psychedelic therapies might repair the physical toll of chronic stress. The study, “Psilocybin restores behavioral and neuroplastic deficits induced by chronic stress in rats,” was authored by Agnieszka Bysiek, Izabela Szpręgiel, Adam Wojtas, Marzena Maćkowiak, Agnieszka Wawrzczak-Bargieła, Monika Leśkiewicz, Ewa Trojan, Katarzyna Kamińska, Weronika Kumorek, Wiktor Bilecki, and Krystyna Gołembiowska.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #PsilocybinTherapy #PsychedelicResearch #DepressionTreatment #Neuroplasticity #HippocampusHealing #StressHormones #BrainBDNF #AnimalStudy #MentalHealthScience #InnovativeNeurology
-
Psychedelic Research Edges Toward Nuance, Moving Beyond Broad Strokes
New research shows low sensory changes from psychedelics like psilocybin may improve therapy for depression and PTSD. Learn how.
#PsychedelicResearch, #PsilocybinTherapy, #MentalHealth, #PTSD, #Depression
https://newsletter.tf/psychedelics-low-sensory-changes-therapy-outcomes/
-
Scientists now believe small sensory changes from psychedelics are key to therapy, not just side effects. This is a big shift from older ideas.
#PsychedelicResearch, #PsilocybinTherapy, #MentalHealth, #PTSD, #Depression
https://newsletter.tf/psychedelics-low-sensory-changes-therapy-outcomes/ -
Psilocybin therapy offers relief from multiple psychiatric symptoms in cancer patients https://www.psypost.org/psilocybin-therapy-offers-relief-from-multiple-psychiatric-symptoms-in-cancer-patients/?utm_source=dlvr.it&utm_medium=mastodon #PsilocybinTherapy #Psychotherapy #CancerPatients #PsychiatricSymptoms #MentalHealth
-
Majority of Americans support supervised use of psilocybin for mental health and well-being https://www.psypost.org/majority-of-americans-support-supervised-use-of-psilocybin-for-mental-health-and-well-being/?utm_source=dlvr.it&utm_medium=mastodon #PsilocybinTherapy #MentalHealth #WellBeing #PersonalGrowth #Psychedelics
-
https://psychedelictherapy.institute/ketamine-research-1/esketamine-psiclybin-number-to-treat-depression A comparison between #psilocybin and #esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review (Wong, et al, 2024) suggests safety and efficacy for #depression #numbertotreat #psychedelics #ketaminetherapy #psilocybintherapy #psychedelicassistedtherapy #psychedelics
-
Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder (Weiss, et al, 2024)
https://ketaminetherapypalmsprings.com/psilocybinassisted-therapy/psilocybin-therapy-psychedelic-experience #psilocybin #psychedelic #thepsychedelicexperience #egodeath #mysticalexperience #psychedelics #psychedelicresearch #psilocybintherapy #psychedelicassistedpsychotherapy